🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 63 of 151

  1. IONIS-FB-LRx

    IONIS PHARMACEUTICALS INC

    Primary IgA Nephropathy

    phase 2 small molecule completed

    1 trial

  2. IONIS-FB-LRx

    IONIS PHARMACEUTICALS INC

    Macular Degeneration

    phase 2 small molecule completed

    1 trial

  3. IONIS-FB-Lrx

    IONIS PHARMACEUTICALS INC

    Geographic Atrophy

    phase 2 small molecule terminated

    1 trial

  4. IONIS-HBVRx

    IONIS PHARMACEUTICALS INC

    Hepatitis B

    phase 2 small molecule completed

    1 trial

  5. IONIS-PKKRx (ISIS 546254)

    IONIS PHARMACEUTICALS INC

    Chronic Migraine

    phase 2 small molecule completed

    1 trial

  6. IONIS-STAT3Rx

    IONIS PHARMACEUTICALS INC

    Advanced Cancers

    phase 2 small molecule completed

    1 trial

  7. IOV-3001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  8. IOV-4001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  9. IPH6501

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  10. IPILIMUMAB, AXITINIB, PF-08634404, AXITINIB

    Pfizer Australia Pty Ltd

    ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    phase 2 small molecule active

    1 trial

  11. IPILIMUMAB, MELPHALAN , NIVOLUMAB

    Disc Medicine

    metastasized melonama uveal

    phase 2 small molecule active

    1 trial

  12. IPILIMUMAB, NIVOLUMAB

    Ningbo Cancer Hospital

    type B3 thymoma and thymic carcinoma

    phase 2 small molecule active

    1 trial

  13. IPN01195, IPN01195

    Ipsen

    Advanced Solid Tumour

    phase 2 small molecule active

    1 trial

  14. IPN01203

    Ipsen

    Advanced Solid Tumor, Metastatic Solid Tumor

    phase 2 small molecule active

    1 trial

  15. IPN10200

    Ipsen

    Episodic Migraine

    phase 2 mab active

    1 trial

  16. IPN10200 placebo, DYSPORT 300 UNITES SPEYWOOD, poudre pour solution injectable, IPN10200

    Ipsen

    Treatment of Moderate to Severe Upper Facial Lines

    phase 2 small molecule active

    1 trial

  17. IPN10200 placebo, Powder for solution for injection, DYSPORT 500 UNITES SPEYWOOD, poudre pour solution injectable

    Ipsen

    Upper limb spasticity after stroke or traumatic brain injury

    phase 2 small molecule active

    1 trial

  18. IPN10200, IPN10200 placebo

    Ipsen

    Episodic Migraine Chronic Migraine

    phase 2 small molecule active

    1 trial

  19. IPN60300

    Ipsen

    Advanced or metastatic solid tumours

    phase 2 small molecule active

    1 trial

  20. IPSTYL “120 mg soluzione iniettabile in siringa preriempita”, METFORMINA TEVA 850 mg compresse rivestite con film

    Fondazione Telethon ETS

    advanced progressive gastro-intestinal or lung carcinoids

    phase 2 small molecule active

    1 trial

  21. IPTACOPAN, Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023)

    Novartis Pharmaceuticals

    active antineutrophilic cytoplasmic antibody (ANCA) associated vasculitis

    phase 2 small molecule active

    1 trial

  22. IR Viloxazine

    SUPERNUS PHARMACEUTICALS, INC.

    Attention-Deficit/Hyperactivity Disorder (ADHD)

    phase 2 small molecule completed

    1 trial

  23. IR-TPM (Topamax)

    SUPERNUS PHARMACEUTICALS, INC.

    Migraine

    phase 2 small molecule terminated

    1 trial

  24. IRINOTECAN, CALCIUM LEVOFOLINATE, ivonescimab, FOLINIC ACID, OXALIPLATIN, PACLITAXEL, FLUOROURACIL

    Ningbo Cancer Hospital

    Metastatic or locally advanced irresectable (stage IV) gastric cancer (GC) or esophagogastric junction cancer (EGJC), with and without actionable biomarker (HER2/Claudin18.2)

    phase 2 small molecule active

    1 trial

  25. IRINOTECAN, FLUOROURACIL , CETUXIMAB , ENCORAFENIB , SODIUM FOLINATE

    Fondazione Telethon ETS

    Patients affected by mCRC harbouring BRAF V600E

    phase 2 small molecule active

    1 trial

  26. IRINOTECAN, FOLINIC ACID, FLUOROURACIL, DOMVANALIMAB, FLUOROURACIL, ZIMBERELIMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    stomach cancer, Esophage, gastro-oesophageal junction adenocarcinoma

    phase 2 small molecule active

    1 trial

  27. IRINOTECAN, lurbinectedin

    Lacuna Pharma Pty Ltd

    Selected Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  28. IRX4204

    IO Biotech

    Psoriasis

    phase 2 small molecule on hold

    1 trial

  29. ISA101b

    Regeneron UK Limited

    Squamous Cell Carcinoma of the Oropharynx

    phase 2 mab active

    2 trials

  30. ISATUXIMAB

    Pari Pharma GmbH

    Isatuximab in type I cryoglobulinaemia: A prospective pilot study

    phase 2 small molecule active

    1 trial

  31. ISIS 104838

    IONIS PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  32. ISIS 113715

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    5 trials

  33. ISIS 14803

    IONIS PHARMACEUTICALS INC

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  34. ISIS 14803, peginterferon alfa, ribavirin

    IONIS PHARMACEUTICALS INC

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  35. ISIS 2503

    IONIS PHARMACEUTICALS INC

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  36. ISIS 301012

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia, Familial

    phase 2 small molecule completed

    1 trial

  37. ISIS 301012 or Placebo

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia, Familial

    phase 2 small molecule completed

    1 trial

  38. ISIS 301012 or Placebo

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule completed

    2 trials

  39. ISIS 416858

    IONIS PHARMACEUTICALS INC

    End-stage Renal Disease (ESRD)

    phase 2 small molecule completed

    2 trials

  40. ISIS 443139 10 mg

    IONIS PHARMACEUTICALS INC

    Huntington's Disease

    phase 2 small molecule completed

    1 trial

  41. ISIS 678354

    IONIS PHARMACEUTICALS INC

    Hypertriglyceridemia

    phase 2 small molecule completed

    1 trial

  42. ISIS 681257

    IONIS PHARMACEUTICALS INC

    Elevated Lipoprotein(a)

    phase 2 small molecule completed

    1 trial

  43. ISIS 702843

    IONIS PHARMACEUTICALS INC

    Polycythemia Vera

    phase 2 small molecule active

    1 trial

  44. ISIS 721744

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema

    phase 2 small molecule active

    1 trial

  45. ISIS 721744

    IONIS PHARMACEUTICALS INC

    Covid19

    phase 2 small molecule completed

    1 trial

  46. ISIS CRP Rx

    IONIS PHARMACEUTICALS INC

    Paroxysmal Atrial Fibrillation

    phase 2 small molecule completed

    1 trial

  47. ISIS CRP Rx or Placebo

    IONIS PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  48. ISIS EIF4E Rx

    IONIS PHARMACEUTICALS INC

    Castrate-Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.